Published in J Vis Exp on July 27, 2010
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol (2012) 1.49
The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis (2011) 1.14
Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan Leishmania infantum chagasi. Infect Immun (2010) 1.06
Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis. PLoS Negl Trop Dis (2012) 1.00
Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferase. PLoS Negl Trop Dis (2013) 0.96
Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl Trop Dis (2011) 0.94
In vivo imaging of mice infected with bioluminescent Trypanosoma cruzi unveils novel sites of infection. Parasit Vectors (2014) 0.89
Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells. J Biol Inorg Chem (2013) 0.85
A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J Biomol Screen (2014) 0.85
Non-invasive in vivo study of the Trypanosoma vivax infectious process consolidates the brain commitment in late infections. PLoS Negl Trop Dis (2013) 0.84
A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis. PLoS Negl Trop Dis (2015) 0.83
Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs. Antimicrob Agents Chemother (2013) 0.77
Evaluation of α,β-unsaturated ketones as antileishmanial agents. Antimicrob Agents Chemother (2015) 0.76
A step beyond BRET: Fluorescence by Unbound Excitation from Luminescence (FUEL). J Vis Exp (2014) 0.76
Concomitant Immunity Induced by Persistent Leishmania major Does Not Preclude Secondary Re-Infection: Implications for Genetic Exchange, Diversity and Vaccination. PLoS Negl Trop Dis (2016) 0.76
Thymol and eugenol derivatives as potential antileishmanial agents. Bioorg Med Chem (2014) 0.75
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis. Antimicrob Agents Chemother (2017) 0.75
Experimental infection of Phlebotomus perniciosus by bioluminescent Leishmania infantum using murine model and artificial feeder. Mem Inst Oswaldo Cruz (2016) 0.75
Photonic detection of bacterial pathogens in living hosts. Mol Microbiol (1995) 5.24
Identification of an infective stage of Leishmania promastigotes. Science (1984) 4.00
The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 3.63
A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol (2001) 2.72
Development of a stable Leishmania expression vector and application to the study of parasite surface antigen genes. Proc Natl Acad Sci U S A (1990) 2.52
Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol (2000) 2.10
Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect Immun (1987) 1.74
Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol (2005) 1.67
Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol (1990) 1.54
The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med (1988) 1.51
Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J Immunol (1996) 1.39
Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun (2003) 1.38
Two functionally divergent UDP-Gal nucleotide sugar transporters participate in phosphoglycan synthesis in Leishmania major. J Biol Chem (2007) 1.35
Hock immunization: a humane alternative to mouse footpad injections. J Immunol Methods (2007) 1.23
Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. J Immunol (2006) 1.19
Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model. PLoS Negl Trop Dis (2007) 1.16
Induced biliary excretion of Listeria monocytogenes. Infect Immun (2006) 1.13
Regulation of GP63 mRNA stability in promastigotes of virulent and attenuated Leishmania chagasi. Mol Biochem Parasitol (2001) 1.04
Imaging Leishmania development in their host cells. Trends Parasitol (2009) 0.88
Construction and analysis of Leishmania tarentolae transgenic strains free of selection markers. Mol Biochem Parasitol (2007) 0.86
Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major. Infect Immun (2000) 0.83
The genome of the kinetoplastid parasite, Leishmania major. Science (2005) 8.64
Illness after international travel. N Engl J Med (2002) 3.56
GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med (2013) 3.37
Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol (2013) 3.32
Demonstration of genetic exchange during cyclical development of Leishmania in the sand fly vector. Science (2009) 3.28
Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med (2004) 3.24
Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem Parasitol (2003) 2.45
The globalization of healthcare: implications of medical tourism for the infectious disease clinician. Clin Infect Dis (2013) 2.42
Transmission of dengue virus without a mosquito vector: nosocomial mucocutaneous transmission and other routes of transmission. Clin Infect Dis (2004) 2.30
An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol (2003) 2.07
Hepatitis B screening in US travelers seen at the Boston area travel medicine network. J Travel Med (2013) 2.00
Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol (2011) 1.97
The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol Biochem Parasitol (2003) 1.93
Migratory dermal dendritic cells act as rapid sensors of protozoan parasites. PLoS Pathog (2008) 1.90
Persistence without pathology in phosphoglycan-deficient Leishmania major. Science (2003) 1.89
The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A (2003) 1.89
Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science (2011) 1.88
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79
Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther (2009) 1.75
Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog (2010) 1.69
Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem (2012) 1.67
Transposon mutagenesis of Mycobacterium marinum identifies a locus linking pigmentation and intracellular survival. Infect Immun (2003) 1.59
A lipophosphoglycan-independent development of Leishmania in permissive sand flies. Microbes Infect (2007) 1.58
Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J Gen Virol (2005) 1.57
Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J Biol Chem (2003) 1.52
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol (2012) 1.49
Knowledge, attitudes, and practices of US practitioners who provide pre-travel advice. J Travel Med (2014) 1.48
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun (2002) 1.46
Dengue and chikungunya infections in travelers. Curr Opin Infect Dis (2010) 1.45
Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol (2004) 1.45
Prevention of malaria in long-term travelers. JAMA (2006) 1.44
Redirection of sphingolipid metabolism toward de novo synthesis of ethanolamine in Leishmania. EMBO J (2007) 1.44
The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg (2002) 1.43
Prevalence of dengue virus infection in US travelers who have lived in or traveled to dengue-endemic countries. J Travel Med (2013) 1.43
Sphingolipids are essential for differentiation but not growth in Leishmania. EMBO J (2003) 1.40
A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res (2011) 1.40
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 1.38
Leishmania salvage and remodelling of host sphingolipids in amastigote survival and acidocalcisome biogenesis. Mol Microbiol (2005) 1.38
Breastfeeding travelers: precautions and recommendations. J Travel Med (2010) 1.38
IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis (2006) 1.38
Two functionally divergent UDP-Gal nucleotide sugar transporters participate in phosphoglycan synthesis in Leishmania major. J Biol Chem (2007) 1.35
An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J Immunol (2007) 1.35
Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol (2011) 1.34
Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol (2003) 1.34
Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expr Purif (2002) 1.33
Threat of dengue to blood safety in dengue-endemic countries. Emerg Infect Dis (2009) 1.32
Regulated expression of the Leishmania major surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins. Proc Natl Acad Sci U S A (2009) 1.30
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi. Infect Immun (2004) 1.29
Characterization of a defensin from the sand fly Phlebotomus duboscqi induced by challenge with bacteria or the protozoan parasite Leishmania major. Infect Immun (2004) 1.29
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog (2013) 1.28
An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand J Infect Dis (2004) 1.27
Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA (2007) 1.26
Developmentally regulated sphingolipid synthesis in African trypanosomes. Mol Microbiol (2008) 1.26
Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood (2012) 1.25
Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major. Infect Immun (2007) 1.19
Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol (2003) 1.17
Phylogenomic and functional analysis of pterin-4a-carbinolamine dehydratase family (COG2154) proteins in plants and microorganisms. Plant Physiol (2008) 1.16
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
Expression profiling using random genomic DNA microarrays identifies differentially expressed genes associated with three major developmental stages of the protozoan parasite Leishmania major. Mol Biochem Parasitol (2004) 1.14
The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis (2011) 1.14
Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine (2010) 1.13
Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother (2011) 1.11
Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis (2007) 1.11
Illness in long-term travelers visiting GeoSentinel clinics. Emerg Infect Dis (2009) 1.10
Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model. Exp Parasitol (2007) 1.10
Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan. J Infect Dis (2007) 1.09
Adult-onset tufted angioma: a case report and review of the literature. Cutis (2006) 1.09
Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis (2010) 1.09
Leishmania RNA virus: when the host pays the toll. Front Cell Infect Microbiol (2012) 1.08
Phosphoproteome dynamics reveal heat-shock protein complexes specific to the Leishmania donovani infectious stage. Proc Natl Acad Sci U S A (2010) 1.08
Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes. Infect Immun (2010) 1.07
The role of microRNAs miR-200b and miR-200c in TLR4 signaling and NF-κB activation. Innate Immun (2012) 1.07
Phospholipid and sphingolipid metabolism in Leishmania. Mol Biochem Parasitol (2009) 1.07
Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts. Exp Parasitol (2009) 1.06
Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan Leishmania infantum chagasi. Infect Immun (2010) 1.06
Travel-associated illness trends and clusters, 2000-2010. Emerg Infect Dis (2013) 1.05
Leishmania donovani ornithine decarboxylase is indispensable for parasite survival in the mammalian host. Infect Immun (2008) 1.05
Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis (2008) 1.05
Hyperkeratotic plaques on the palms and soles. Palmoplantar lichen planus, hyperkeratotic variant. Arch Dermatol (2004) 1.05
Sex and gender differences in travel-associated disease. Clin Infect Dis (2010) 1.05
Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun (2004) 1.05
Characterization of inositol phosphorylceramides from Leishmania major by tandem mass spectrometry with electrospray ionization. J Am Soc Mass Spectrom (2007) 1.04
Functional identification of galactosyltransferases (SCGs) required for species-specific modifications of the lipophosphoglycan adhesin controlling Leishmania major-sand fly interactions. J Biol Chem (2003) 1.04
Biosynthesis of the major surface protease GP63 of Leishmania chagasi. Mol Biochem Parasitol (2002) 1.04
Disseminated Strongyloides stercoralis: hyperinfection during medical immunosuppression. J Am Acad Dermatol (2010) 1.03
Cigarette smoking decreases global microRNA expression in human alveolar macrophages. PLoS One (2012) 1.03
Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity. Proc Natl Acad Sci U S A (2010) 1.03
Leishmania major glycosylation mutants require phosphoglycans (lpg2-) but not lipophosphoglycan (lpg1-) for survival in permissive sand fly vectors. PLoS Negl Trop Dis (2010) 1.02
Listeria as a vaccine vector. Microbes Infect (2007) 1.02
A function for a specific zinc metalloprotease of African trypanosomes. PLoS Pathog (2007) 1.02